Investment analysts at BTIG Research began coverage on shares of Quanterix (NASDAQ:QTRX) in a research report issued on Tuesday. The brokerage set a “buy” rating and a $26.00 price target on the stock. BTIG Research’s price target indicates a potential upside of 36.27% from the company’s current price.
A number of other equities research analysts have also recently weighed in on QTRX. JPMorgan Chase & Co. started coverage on Quanterix in a report on Tuesday. They issued an “overweight” rating on the stock. Cowen started coverage on Quanterix in a report on Tuesday. They issued an “outperform” rating on the stock.
Quanterix (QTRX) traded down $0.47 on Tuesday, hitting $19.08. The company had a trading volume of 205,700 shares, compared to its average volume of 230,550. Quanterix has a 1-year low of $15.56 and a 1-year high of $23.70.
In related news, insider E Kevin Hrusovsky bought 34,000 shares of the stock in a transaction on Monday, December 11th. The shares were purchased at an average price of $15.00 per share, for a total transaction of $510,000.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Venture Fund Viii Overage Arch bought 266,000 shares of the stock in a transaction on Monday, December 11th. The shares were bought at an average price of $15.00 per share, for a total transaction of $3,990,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 500,000 shares of company stock worth $7,500,000.
TRADEMARK VIOLATION NOTICE: “Quanterix (QTRX) Now Covered by BTIG Research” was published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://transcriptdaily.com/2018/01/04/quanterix-qtrx-now-covered-by-btig-research.html.
Quanterix Corporation is a United States-based company, which is a developer of tools in high definition diagnostics. The Company offers single molecule array (Simoa) platform, whcich uses single molecule measurements to access proteins. Simoa focuses on research and clinical testing applications. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.